Back to search results
NCT06345443

NRM on Vascular Perfusion in Healthy Adults

Enrolling by Invitation
NAAges 35–70InterventionalPrevention
Mayo Clinic
~200 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Nicotinamide Riboside MalatePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Reduced Endothelial Stiffness
Measured over Baseline to End of study at 12 weeks

Conditions

Vascular Stiffness

Explore related trials

Healthy Volunteers

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Ryan Hurt, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
  • Brent Bauer, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\>= 35 and \<=70
Provides consent to participate in the study
Not pregnant at time of consent
Understands and agrees to follow all study procedures and limitations
Have no contraindicating comorbid health condition as determined by the clinical investigators

Exclusion

Pregnant, nursing, or trying to conceive
BMI Restrictions: \<35
Allergy or sensitivity to study agent ingredients
Hypertension treated with medication
Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study.
Surgery planned during the course of the trial
History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke
History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis.
Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index \>40 kg m-2), or weight stable for at least 3 months prior to enrolling in the study (defined as \>2 kg change in body mass).
An unstable medical or mental health condition as determined by the physician investigator.

What this trial measures

  • Number of Participants with Reduced Endothelial StiffnessBaseline to End of study at 12 weeks

    Endothelial Peripheral Arterial Tonometry testing will be used to assess endothelial stiffness changes over study